Bliss GVS Pharma shareholders approve Santosh Parab director appointment
- Santosh Parab appointed as Non-Executive Non-Independent Director via postal ballot
- Total votes in favour stood at 60,481,459, representing 97.04% of votes polled
- Public institutions recorded 15.53% opposition, contrasting with near-unanimous retail support
- Voting period ran from August 21, 2026, to September 19, 2026, via CDSL e-voting

*this image is generated using AI for illustrative purposes only.
Bliss GVS Pharma shareholders approved the appointment of Santosh Parab as a Non-Executive and Non-Independent Director through a postal ballot process concluded on September 22, 2026.
The resolution, passed as an Ordinary Resolution, received overwhelming support from the voting base. Out of the total votes polled, 60,481,459 were cast in favour, while 1,841,768 votes were against. This resulted in a favourable vote percentage of 97.04% on the total votes polled.
The voting period for the remote e-voting facility, provided by Central Depository Services (India) Limited, commenced on August 21, 2026, and ended on September 19, 2026. The scrutinizer’s report was submitted by Vijay Yadav of M/s. AVS & Associates, confirming the compliance with the Companies Act, 2013, and SEBI listing regulations.
Voting breakdown by shareholder category
The voting results reveal distinct patterns in participation and support across different shareholder groups. Promoters and promoter group members voted unanimously in favour, while public institutional holders showed notable dissent.
| Category | Shares Held | Votes Polled | Votes For | Votes Against | % In Favour |
|---|---|---|---|---|---|
| Promoter and Promoter Group | 3,71,30,124 | 3,24,37,024 | 3,24,37,024 | 0 | 100.00% |
| Public Institutions | 1,69,39,697 | 1,18,54,291 | 1,00,13,243 | 18,41,048 | 84.47% |
| Public Non-Institutions | 5,21,74,151 | 1,80,31,912 | 1,80,31,192 | 720 | 99.99% |
| Total | 10,62,43,972 | 6,23,23,227 | 6,04,81,459 | 1,841,768 | 97.04% |
What the numbers show
A divergence exists between institutional and retail sentiment regarding the director appointment. While Public Non-Institutional shareholders (retail investors) voted overwhelmingly in favour with only 720 dissenting votes out of over 18 million polled, Public Institutional holders recorded a significant 15.53% opposition rate. This suggests that institutional investors may have had specific concerns or governance considerations that differed from the broader retail base, although the overall resolution passed comfortably due to strong promoter backing.
Historical Stock Returns for Bliss GVS Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.00% | -3.65% | +19.94% | +230.40% | +361.44% | +521.01% |
What specific governance or strategic concerns drove the 15.53% dissent among public institutional shareholders regarding Santosh Parab's appointment?
How might Parab's role as a Non-Executive, Non-Independent Director influence Bliss GVS Pharma's upcoming capital allocation or M&A strategies?
Will the notable institutional opposition trigger further scrutiny or activism from proxy advisory firms in future shareholder votes?


































